Intrexon | XON - Passività Correnti





Passività Correnti Cambiamento Data
Agenus USD 323.49M 36.36M 2025-12
Alaunos Therapeutics USD 921K 153K 2025-09
Amgen USD 25.49B 3.7B 2025-12
Anika Therapeutics USD 21.91M 2.82M 2025-12
Arrowhead Research USD 347.42M 151.94M 2025-12
AstraZeneca USD 30.62B 3.44B 2025-12
Bristol-Myers Squibb USD 28.14B 608M 2025-09
Gilead Sciences USD 11.81B 485M 2025-12
GlaxoSmithKline GBP 21.39B 57M 2025-12
Heron Therapeutics USD 96.1M 6.39M 2025-12
Incyte USD 1.52B 176.44M 2025-12
Intrexon USD 23.02M 38K 2024-06
Karyopharm Therapeutics USD 87.16M 12.06M 2025-09
Ligand Pharmaceuticals USD 37.45M 6.91M 2025-12
MacroGenics USD 43.11M 1.36M 2025-12
MannKind USD 171.03M 61.9M 2025-12
Merck USD 28.63B 2.59B 2025-09
Novartis USD 27.28B 4.72B 2025-12
Rigel Pharmaceuticals USD 94.4M 7.76M 2025-09
Roche Holding CHF 28B 421M 2025-12
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Thermo Fisher Scientific USD 15.19B 301M 2025-12
Veracyte USD 59.94M 12.22M 2025-12
Xencor USD 95.91M 9.42M 2025-12